GlassScriptPhysician profile
Jeffrey William Hermann
NPI 1376603597
$9,860.50
in general payments reported to CMS, 2019-2025
25 companies · $2,727 in 2025
The $2,727 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $855 · 2021: $317 · 2022: $1,413 · 2023: $1,796 · 2024: $1,994 · 2025: $2,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,405 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,405.42 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,194.24 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $1,148.73 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $847.43 | 2019-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $812.53 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $792.91 | 2019-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $746.93 | 2020-2025 | Uzedy, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $648.40 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $603.40 | 2019-2025 | Ingrezza |
| Corium, LLC | $500.21 | 2022-2025 | Azstarys, Azstarys |
| Janssen Pharmaceuticals, INC | $381.37 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $364.43 | 2023-2025 | Auvelity |
| Tris Pharma INC | $358.85 | 2019-2025 | Dyanavel Xr |
| Lundbeck LLC | $272.14 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $240.31 | 2021-2025 | Trintellix |
| Abbvie INC. | $234.79 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $201.03 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $167.15 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $133.80 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $83.54 | 2019-2020 | |
| Shire North American Group INC | $33.39 | 2019 | |
| Vanda Pharmaceuticals INC. | $31.84 | 2025 | Fanapt |
| Jazz Pharmaceuticals INC. | $20.72 | 2020 | |
| Vertical Pharmaceuticals, LLC | $16.43 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.19 | 2024 | Quviviq |
| Neuronetics, INC. | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.